Companies › Bisirna Therapeutics (Suzhou)
2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Other; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VSA012 Complement system inhibitor | – | Phase 1 | Healthy Volunteers | Jun 2027 |
| BSA204 LPA antisense oligonucleotide inhibitor | LPA | Phase 1 | Dyslipidemias | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06766929 | VSA012 | Phase 1 | Healthy Volunteers | Other | Jun 2027 |
| NCT07551505 | BSA204 | Phase 1 | Dyslipidemias | Cardiovascular | Jul 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.